News & Articles
6/12/2024
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic Definitions
6/11/2024
GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024
6/4/2024
World’s Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment Milestone
5/17/2024
Real-World Evidence Leader in Inflammatory Bowel Disease, Target RWE, Announces Expanded Footprint with TARGET-GASTRO Registry of 30,000+ Patients At Digestive Disease Week
4/15/2024
AGA Announces New Partnership with Target RWE to Gather Real World Data on Eosinophilic Esophagitis (EoE)
3/8/2024
Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024
1/4/2024
Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions
12/4/2023
Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care
11/13/2023
Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?
10/23/2023
Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population
11/13/2023
TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options
11/10/2023
Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases
9/21/2023
New Eosinophilic Gastrointestinal Disorders (EGIDs) Real World Registry Surpasses 1,000 Patient Milestone
8/23/2023
Target RWE's Cutting-Edge Analytical Solutions Launched to Propel Real-World Evidence Generation
8/22/2023
Target RWE Strengthens Industry Leadership Position with Novel Real World Evidence Approaches Presented at ICPE 2023
6/21/2023
World-Leading Real World Data Registry, TARGET-NASH, Surpasses 7,000+ Enrolled Patients and 500,000+ Months of Patient Follow-Up
6/2/2023
Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023
5/8/2023
Real World Evidence Leader Target RWE Shares Expansion and Update on TARGET-GASTRO Longitudinal Study During Digestive Disease Week 2023
3/30/2023
Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH
3/8/2023
Ewa Kleczyk, PhD Featured on CIO Views Cover for March – A Memento to Women’s History Month & International Women’s Day
2/28/2023
Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex Diseases
1/11/2023
Target RWE Launches 35 New Disease State Registries in Complex Indications with High Unmet Medical Needs and Rapidly Evolving Therapies
10/18/2022
Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality Collaborative
8/25/2022
New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)
8/24/2022
Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition
8/23/2022
Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022
7/20/2022
Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population
6/24/2022
Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022
6/17/2022
Target RWE Leads Industry Discussion of Fusion Designs and Teaching Advanced Epidemiologic Methods at SER 2022
5/22/2022
New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients Who Had Histologic Inflammation on Baseline Biopsy
5/20/2022
Target RWE’s Allison Chandler Named One of Triangle Business Journal’s “40 Under 40”
4/5/2022
Blog - What’s the risk? Impacts of Parametric Assumptions for Causal Analysis of Time-to-event Outcomes
3/29/2022
Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in Children
3/8/2022
TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, Discontinuation
11/3/2021
Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology Reporting
10/19/2021
Blog - One Model to Rule Them All: Using a Single Model to Control for Confounding and Informative Censoring
9/13/2021
Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting
7/1/2021
Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
6/22/2021
Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients
6/15/2021
TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease
5/25/2021
Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission
5/23/2021
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population
2/22/2021
TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver Biopsy
1/15/2021
Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform
11/13/2020
Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities
10/1/2020
TARGET-DERM Real-World Study Success Leads To Global Site Expansion And New Dermatologic Conditions
9/24/2020
TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid Use
9/9/2020
Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH Study
8/28/2020
Target RWE Builds Growing COVID-19 Data Set of 70,000+ Patients, Announces Published Data Findings
5/7/2020
Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
3/17/2020
TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
11/21/2019
TARGET-IBD Research Receives Presidential Poster Award And Outstanding Presenter Award At 2019 American College Of Gastroenterology Annual Scientific Meeting
2/27/2019
TARGET PharmaSolutions to Advance Dermatology Research, including Atopic Dermatitis, through New Collaboration
2/13/2019
TARGET PharmaSolutions Launches TARGET-DERM Real-World Observational Study to Advance the Understanding of Atopic Dermatitis (Eczema) and Other Immune-Mediated Inflammatory Skin Conditions
12/3/2018
TARGET PharmaSolutions Announces Partnership with Bristol Myers Squibb to Advance Inflammatory Bowel Disease (IBD) Research
11/20/2018
TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
10/31/2018
TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B
10/20/2017
Why big pharma is partnering with this Chapel Hill data company - Triangle Business Journal
10/19/2017
Boehringer Ingelheim partners with TARGET PharmaSolutions to Progress NASH Research
10/19/2017
Intercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
10/12/2017
Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
8/2/2017
TARGET PharmaSolutions Enrolls First Participant in its Inflammatory Bowel Disease (IBD) Community
11/10/2016
TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World Data
11/1/2016